Psyence Biomedical Ltd. PBMWW
Nov 4, 2026, 9:30 AM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 848
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 200
- Open
- 0.024
- Previous close
- 0.0119
- Day's range
- 0.0119 – 0.0119
- 52-week range
- 0.0119 – 0.0119
- Beta
- -0.42
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -1.71M
- Total cash
- 733.19K
- Total debt
- 7.66M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Consensus EPS estimate 0.00.
About Psyence Biomedical Ltd.
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- psyencebiomed.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PBMWW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Cowen and Company, LLC | 9.34% | 1,220,986 | 23.20K | Sep 29, 2024 |
| Polar Asset Management Partners Inc. | 5.61% | 733,000 | 13.93K | Sep 29, 2024 |
| MMCAP International, Inc. SPC | 4.59% | 600,000 | 11.40K | Sep 29, 2024 |
| Calamos Advisors LLC | 3.83% | 500,000 | 9.50K | Sep 29, 2024 |
| Cantor Fitzgerald, L.P. | 3.58% | 468,500 | 8.90K | Sep 29, 2024 |
| Saba Capital Management, L.P. | 2.28% | 297,847 | 5.66K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Calamos Market Neutral Income Fund | 3.83% | 500,000 | 9.50K | Oct 30, 2024 |
| Merger Fund, The | 0.65% | 85,245 | 1.62K | Sep 29, 2024 |
| Saba Capital Income & Opportunities Fd | 0.23% | 30,398 | 577 | Jul 30, 2024 |
| JNL Series Trust-JNL/Multi Manager Alternative Fund | 0.03% | 4,024 | 76 | Sep 29, 2024 |
| Principal Global Multi Strategy Fd | 0.01% | 974 | 18 | Aug 30, 2024 |
| WCM Alternatives Credit Event Fund | 0.01% | 733 | 13 | Sep 29, 2024 |